ERBB2 and triple-negative breast carcinoma: In contrast, triple-negative breast cancers (TNBCs, which lack clinical expression of estrogen and progesterone receptors while showing overexpression of the HER-2 receptor) cannot be treated with current endocrine or HER2-targeting therapies.